Zalcitabine Toxicity

What is Zalcitabine Toxicity?

Zalcitabine toxicity refers to the adverse clinical effects that occur when the antiretroviral medication zalcitabine (brand name Hivid) accumulates to harmful levels in the body. Zalcitabine is a nucleoside reverse‑transcriptase inhibitor (NRTI) that was once used to treat human immunodeficiency virus (HIV) infection. Although it is now rarely prescribed in the United States, patients who were treated before its market withdrawal (2006) or who receive it in other countries may experience toxicity if dosing is inappropriate, renal or hepatic function declines, or drug interactions raise serum concentrations.

Toxicity can manifest as hematologic abnormalities, neurologic disturbances, gastrointestinal upset, and metabolic derangements. Because many of these signs mimic other HIV‑related conditions, a high index of suspicion is required.

Common Causes

While “zalcitabine toxicity” specifically denotes excess drug effect, several underlying factors increase the risk:

• Improper dosing – using doses that are too high for a patient’s weight or renal function.
• Renal impairment – reduced clearance leads to drug accumulation.
• Hepatic dysfunction – impaired metabolism can raise systemic levels.
• Concurrent nephrotoxic or hepatotoxic medications (e.g., tenofovir, isoniazid).
• Drug–drug interactions that inhibit the enzymes responsible for zalcitabine phosphorylation (e.g., certain protease inhibitors).
• Dehydration or severe electrolyte imbalance – worsens renal excretion.
• Advanced age – physiologic decline in organ function.
• Pregnancy – altered pharmacokinetics may increase exposure.
• Genetic polymorphisms in mitochondrial DNA polymerase gamma, making patients more susceptible to NRTI‑induced mitochondrial toxicity.
• Non‑adherence leading to intermittent dosing – can cause fluctuating drug levels and paradoxical toxicity.

Associated Symptoms

The clinical picture varies but commonly includes:

• Myelosuppression: anemia, neutropenia, or thrombocytopenia leading to fatigue, easy bruising, or infections.
• Peripheral neuropathy: burning, tingling, or numbness in the hands and feet.
• Gastrointestinal upset: nausea, vomiting, abdominal pain, or diarrhea.
• Lactic acidosis: rapid breathing, abdominal discomfort, and a feeling of “flu‑like” malaise.
• Pancreatitis: severe upper‑abdominal pain radiating to the back, often with nausea.
• Hepatotoxicity: jaundice, dark urine, or elevated liver enzymes.
• Hyperlipidemia and insulin resistance, contributing to cardiovascular risk.
• Mitochondrial toxicity: muscle weakness, myopathy, or exercise intolerance.

When to See a Doctor

Prompt medical evaluation is essential if you experience any of the following while taking zalcitabine or after recent discontinuation:

• Fever > 38°C (100.4°F) with chills or new‑onset cough.
• Persistent or worsening nausea, vomiting, or diarrhea for more than 48 hours.
• Sudden onset of severe abdominal pain, especially if radiating to the back.
• Unexplained fatigue, shortness of breath, or palpitations.
• Yellowing of the skin or eyes (jaundice).
• New or worsening numbness/tingling in extremities.
• Unusual bruising, bleeding, or prolonged infections.
• Signs of lactic acidosis (rapid breathing, severe malaise, abdominal pain).

Because many of these symptoms may signal life‑threatening complications, do not wait for them to resolve on their own.

Diagnosis

Diagnosing zalcitabine toxicity involves a combination of clinical assessment, laboratory testing, and sometimes imaging:

1. Detailed medical history

• Drug exposure timeline (dose, duration, adherence).
• Co‑administered medications and supplements.
• Renal and hepatic function background.
• Prior history of mitochondrial or metabolic disorders.

2. Physical examination

• Assess for pallor, lymphadenopathy, hepatosplenomegaly, peripheral neuropathy signs.
• Check vital signs for tachypnea (suggestive of lactic acidosis).

3. Laboratory studies

• Complete blood count (CBC) – to detect anemia, neutropenia, thrombocytopenia.
• Liver function tests (ALT, AST, ALP, bilirubin) – for hepatotoxicity.
• Serum creatinine and estimated GFR – assess renal clearance.
• Lactate level – a lactate > 5 mmol/L raises concern for lactic acidosis.
• Serum amylase/lipase – for pancreatitis.
• Viral load and CD4 count – to evaluate HIV control while adjusting therapy.

4. Additional tests

• Peripheral blood smear (may show macrocytosis).
• Electromyography (EMG) if severe neuropathy is present.
• Imaging (abdominal CT or ultrasound) when pancreatitis or hepatomegaly is suspected.

5. Drug level monitoring

Although routine serum zalcitabine levels are not widely available, some specialized centers can measure intracellular phosphorylated metabolites to confirm accumulation.

Treatment Options

Treatment centers on stopping or adjusting the offending drug, managing complications, and supporting organ function.

1. Discontinuation or dose reduction

• Immediate cessation of zalcitabine is recommended for severe toxicity (grade ≥ 3 per DAIDS criteria).
• If only mild toxicity, a dose reduction with close monitoring may be considered.

2. Substitute antiretroviral regimen

• Switch to a newer NRTI (e.g., emtricitabine, tenofovir alafenamide) or an integrase inhibitor, based on susceptibility testing.
• Consult an HIV specialist to avoid cross‑toxicity.

3. Supportive care for specific complications

• Myelosuppression: Granulocyte colony‑stimulating factor (G‑CSF) for neutropenia; transfusions for severe anemia or thrombocytopenia.
• Peripheral neuropathy: Gabapentin or duloxetine; physical therapy; avoidance of other neurotoxic agents.
• Lactic acidosis: Intravenous sodium bicarbonate, aggressive hydration, and early intensive care unit (ICU) admission; consider dialysis if renal failure coexists.
• Pancreatitis: NPO (nothing by mouth), IV fluids, analgesia, and monitoring of electrolytes.
• Hepatotoxicity: N‑acetylcysteine is not indicated; management is mostly supportive and includes avoiding hepatotoxins.

4. Nutritional and home measures

• Hydration – aim for at least 2 L of water daily unless contraindicated.
• Balanced diet rich in B‑vitamins and antioxidants to support mitochondrial recovery.
• Regular low‑impact exercise (walking, swimming) to maintain muscle strength while neuropathy resolves.
• Vitamin B12 or folate supplementation if macrocytosis is present.

5. Follow‑up monitoring

After discontinuation, repeat CBC, liver enzymes, renal function, and lactate within 1–2 weeks, then monthly until values normalize. Ongoing HIV viral load assessments ensure that alternative therapy maintains virologic suppression.

Prevention Tips

While zalcitabine use has declined, patients and clinicians can still take steps to prevent toxicity:

• Baseline testing – obtain renal, hepatic, and CBC labs before initiating therapy.
• Weight‑based dosing – use the recommended mg/kg dosing schedule.
• Regular monitoring – repeat labs every 3–6 months, more frequently if risk factors exist.
• Medication reconciliation – review all prescriptions, over‑the‑counter drugs, and supplements at each visit.
• Avoid nephrotoxic agents – limit NSAIDs, high‑dose vancomycin, or contrast imaging when possible.
• Stay hydrated – especially during intercurrent illnesses that can precipitate renal injury.
• Promptly report new symptoms – the earlier a problem is recognized, the easier it is to intervene.
• Genetic screening – in research settings, testing for mitochondrial polymerase gamma variants may identify high‑risk individuals.

Emergency Warning Signs

---

Because zalcitabine is an older antiretroviral with a narrow therapeutic window, recognizing toxicity early can prevent serious organ damage and improve outcomes. If you are living with HIV and have a history of zalcitabine use, stay proactive with routine labs and never ignore new or worsening symptoms.

References:

• Mayo Clinic. “Antiretroviral therapy side effects.” mayoclinic.org. Accessed June 2026.
• U.S. Department of Health & Human Services. “Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.” 2024 update.
• World Health Organization. “Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring.” 2023.
• Cleveland Clinic. “Drug‑induced peripheral neuropathy.” my.clevelandclinic.org. 2025.
• NIH National Institute of Allergy and Infectious Diseases. “Nucleoside Reverse Transcriptase Inhibitors.” 2022.
• J. R. Pozniak et al., “Mitochondrial toxicity of older NRTIs: clinical implications,” *Lancet HIV*, vol. 10, no. 5, 2023.